Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit to inhibit IL-4 and IL-13 signaling, has revolutionized the management of moderate-to-severe AD by effectively reducing Th2-mediated inflammation [9]. Here, IL4 is linked to Alzheimer disease.